Literature DB >> 16008579

Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent.

Kathy Triantafilou1, George Orthopoulos, Emmanouil Vakakis, Mohamed Abd Elrahman Ahmed, Douglas T Golenbock, Philipp M Lepper, Martha Triantafilou.   

Abstract

The group B coxsackieviruses are single-stranded RNA viruses that have been implicated in viral myocarditis. Viral infection of the myocardium, as well as the associated inflammatory response are important determinants of the virus-associated myocardial damage. Although these viruses are known as cytopathic viruses that cause death of the host cell, their viral RNA has been shown to persist in cardiac muscle contributing to a chronic inflammatory cardiomyopathy. Thus, it is essential that we understand the mechanism by which Coxasckie B viruses (CBVs) trigger this inflammatory response. In this study we investigated the involvement of Toll-like receptors (TLRs) in the recognition of CBV virions as well as CBV single-stranded RNA. Here we report that the CBV-induced inflammatory response is mediated through TLR8 and to a lesser extent through TLR7.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16008579     DOI: 10.1111/j.1462-5822.2005.00537.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  59 in total

1.  Induction of a broad spectrum of inflammation-related genes by Coxsackievirus B3 requires Interleukin-1 signaling.

Authors:  Fabienne Rehren; Barbara Ritter; Oliver Dittrich-Breiholz; Andreas Henke; Elena Lam; Semra Kati; Michael Kracht; Albert Heim
Journal:  Med Microbiol Immunol       Date:  2012-06-03       Impact factor: 3.402

2.  Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells.

Authors:  Ofer Levy; Eugénie E Suter; Richard L Miller; Michael R Wessels
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

3.  Toll-like receptor 7/8 agonist resiquimod induces late preconditioning in neonatal cardiac myocytes.

Authors:  Yong-yi Wang; Sha Liu; Feng Lian; Wen-gang Yang; Song Xue
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

Review 4.  Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes.

Authors:  K Lind; M H Hühn; M Flodström-Tullberg
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

5.  Altered Toll-like receptor signaling pathways in human type 1 diabetes.

Authors:  Adam J Meyers; Roopali R Shah; Peter A Gottlieb; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2010-08-20       Impact factor: 4.599

Review 6.  Toll-like receptors and corneal innate immunity.

Authors:  Ashok Kumar; Fu-Shin X Yu
Journal:  Curr Mol Med       Date:  2006-05       Impact factor: 2.222

7.  Rotavirus and coxsackievirus infection activated different profiles of toll-like receptors and chemokines in intestinal epithelial cells.

Authors:  Jin Xu; Y Yang; C Wang; B Jiang
Journal:  Inflamm Res       Date:  2009-03-19       Impact factor: 4.575

8.  MDA5 and MAVS mediate type I interferon responses to coxsackie B virus.

Authors:  Jennifer P Wang; Anna Cerny; Damon R Asher; Evelyn A Kurt-Jones; Roderick T Bronson; Robert W Finberg
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

9.  TLR3 deficiency induces chronic inflammatory cardiomyopathy in resistant mice following coxsackievirus B3 infection: role for IL-4.

Authors:  Eric D Abston; Michael J Coronado; Adriana Bucek; Jennifer A Onyimba; Jessica E Brandt; J Augusto Frisancho; Eunyong Kim; Djahida Bedja; Yoon-kyu Sung; Andrea J Radtke; Kathleen L Gabrielson; Wayne Mitzner; DeLisa Fairweather
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-12-19       Impact factor: 3.619

10.  Toll-like receptor 8 polymorphism and coronary artery disease.

Authors:  Zhong Chen; Genshan Ma; Qi Qian; Yuyu Yao; Yi Feng; Chengchun Tang
Journal:  Mol Biol Rep       Date:  2008-11-05       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.